EGFR and non-small cell lung carcinoma: Retrospective studies in NSCLC using ctDNA genotyping for EGFR mutations in the first-line (EGFRL858R/exon19del)22 and second-line (EGFRT790M)23,24 settings have produced response rates similar to studies of therapies directed by tissue-based genotyping.